Nuveen LLC Purchases Shares of 2,656,277 Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Nuveen LLC has acquired a new stake in Teva Pharmaceutical Industries, purchasing 2,656,277 shares valued at approximately $40.83 million, which represents 0.23% of the company's total shares.
• Teva has received mixed ratings from analysts, with seven analysts giving it a buy rating and a consensus price target of $24.71, despite UBS reducing its price target from $24.00 to $23.00.
• The company's latest earnings report showed a positive EPS of $0.66, beating estimates, although revenue of $4.18 billion was below the consensus expectation of $4.34 billion.

Nuveen LLC bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 2,656,277 shares of the company's stock, valued at approximately $40,827,000. Nuveen LLC owned 0.23% of Teva Pharmaceutical Industries as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $39,000. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $43,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $44,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $54,000. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $74,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,001 shares of company stock valued at $996,958. Corporate insiders own 0.49% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TEVA. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. UBS Group lowered their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded down $0.5050 on Tuesday, hitting $17.5550. 12,485,740 shares of the stock were exchanged, compared to its average volume of 12,168,104. The firm's 50 day moving average is $16.69 and its two-hundred day moving average is $16.24. The firm has a market capitalization of $20.13 billion, a PE ratio of -109.72, a P/E/G ratio of 1.06 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.